Vine Leaf Extract Circulation Research Measures Everything But The Heart

The Oasis Health Journal · Submitted October 20, 2026 · 1:02 PM EDT

By Deke Fontaine · Edited by Hal Weinstock

Vine leaf extract is leftover plant matter from the wine industry that someone in Germany looked at in the mid-nineties and decided to test for vascular effects, and it worked, and then everyone who studied it after that was a dermatologist or a phlebologist, which means we now have two decades of research proving it improves microcirculation in your calves and almost nothing measuring whether it does a damn thing for your coronary arteries.

That is the angle here. The molecule works. The target is just cosmically frustrating.

What Vine Leaf Extract Actually Does In Microcirculation Studies

A 2016 study out of Germany tested red vine leaf extract AS195 on human umbilical vein endothelial cells and red blood cells from healthy volunteers. Researchers incubated the cells with the extract at 100 micromolar concentration and measured nitric oxide synthase activation, nitrite concentration, reactive oxygen species levels, and red blood cell deformability. Endothelial NOS and RBC-NOS activation both increased significantly. Nitrite, a marker of nitric oxide production, went up in endothelial cells. Oxidative stress induced by tert-butylhydroperoxide dropped when cells were treated with the extract. S-nitrosylation of red blood cell cytoskeletal proteins increased, and RBC deformability improved, meaning the cells got more flexible and better able to squeeze through capillaries. That is real microcirculation support, measured in actual human cells, published in a real journal.

The study also noted that patients with microvascular disorders show elevated oxidative stress, which limits nitric oxide bioavailability, and the extract appeared to address both problems at once by increasing NOS-dependent NO generation and decreasing ROS content. That is a clean mechanism tied to measurable outcomes in the cells that matter for blood flow.

And then the paper concluded that these effects "may thus account for enhanced microcirculation in both health and disease," cited twelve prior studies on chronic venous insufficiency, and went back to the dermatology bin.

The Compounds Doing The Work Are Not Unique To Legs

A 2025 analysis identified hydroxybenzoic acids, flavonols and stilbenes as the main phenolic compounds in Vitis vinifera leaves. The methanolic extract inhibited lipoxygenase, an enzyme involved in inflammatory responses, with an IC50 of 1.63 micrograms per milliliter. It also showed potent inhibition of nitric oxide production in LPS-stimulated RAW 264.7 cells, which are mouse macrophages used as a standard inflammation model. The extract scavenged free radicals in vitro and reduced oxidative stress induced by hydrogen peroxide in HepG2 liver cells.

Those are systemic antioxidant and anti-inflammatory effects measured in cell culture, not topical effects measured on skin. Flavonoids do not stop being flavonoids when they leave the calf. A compound that relaxes endothelial cells and reduces oxidative stress in one vascular bed theoretically does the same thing in another vascular bed, assuming the compound gets there and the dose is high enough and someone actually measures it.

Nobody has measured it.

We Have Fifteen Trials On Visible Veins And Zero On The Ones That Kill You

A 2025 review on natural products in venous disease management surveyed the literature and found that flavonoids play a vital role in the circulatory system, supporting blood vessels and promoting healthy blood flow, in addition to vasoprotective, antioxidant, anti-inflammatory and anti-platelet properties. The review covered risk factors, symptoms, therapeutic modalities and the role of natural compounds in alleviating symptoms and improving vascular health. It cited dozens of trials on chronic venous insufficiency, varicose veins, leg heaviness, edema and skin changes.

It did not cite a single randomized controlled trial measuring coronary flow reserve, carotid intima-media thickness, endothelial function via flow-mediated dilation, or any other cardiovascular endpoint you would recognize from a statin trial or an aspirin trial or any intervention actually aimed at preventing the thing that ends the argument.

That is not because the researchers are lazy. It is because the original indication for vine leaf extract was chronic venous insufficiency, which is a real condition that affects quality of life and generates a market, and the trials followed the market, and the market was never in cardiology. So we are left with a natural vascular support supplement that improves endothelial function and reduces oxidative stress in every small vessel someone bothered to look at, and a conspicuous silence on the one vascular system whose failure is the leading cause of death in the developed world.

It is like inventing a better seatbelt and only testing it in golf carts because that is who responded to the first survey.

What The Research Shows And What It Very Pointedly Does Not Show

The 2016 German study demonstrated that red vine leaf extract increases NOS-dependent nitric oxide generation, decreases reactive oxygen species, increases antioxidant capacity, improves red blood cell deformability and reduces endothelial cell adhesion in vitro. Those are all mechanisms tied to improved microcirculation and reduced cardiovascular risk in other contexts. The 2025 phytochemical analysis confirmed high flavonol and stilbene content with demonstrated free radical scavenging and lipoxygenase inhibition. A 2022 review on grapevine waste noted that these compounds are raw materials for pharmaceutical, cosmetic and food industries, with health benefits including antioxidant support, immune support and prevention of cardiovascular and neural diseases.

That last line, "prevention of cardiovascular diseases," appears in the conclusion of a review paper citing zero cardiovascular trials of vine leaf extract.

The gap is not subtle. The compound improves the microcirculation. The microcirculation is part of the cardiovascular system. Improving part of a system usually improves the whole system, unless there is some mechanism-specific reason it would not, and nobody has proposed one, because nobody has run the trial that would tell us whether one exists. We are extrapolating from dermatology and hoping the cardiologists notice, and so far they have not.

That does not mean vine leaf extract circulation support does not work for cardiovascular health. It means nobody with a cardiology department and a budget has asked the question cleanly enough to get an answer that would move the field. The research so far tells you it is biologically active, mechanistically plausible and proven effective in microcirculation, which is real circulation, just not the circulation anyone is trying to keep you alive with.

If you are buying it for leg heaviness or visible veins, you are buying it for the indication that has actual human trial data behind it. If you are buying it because you read "supports healthy circulation" on a label and assumed that meant your coronary arteries, you are buying it for an indication that is mechanistically reasonable, supported by cell culture work and in vitro studies, and entirely unproven in the population and the vascular bed where it would actually matter.

The small flaw is that this is wine industry waste that got studied because someone in a phlebology department had access to it and a hypothesis about leg swelling. The large flaw is that two decades later we still do not have the cardiovascular trial that would settle whether the hypothesis applies to the part of the vascular system that everyone actually worries about. You can buy red vine leaf extract in capsules, you can read fifteen studies on microcirculation, and you can wonder loudly why nobody has run the one study that would tell us if any of this translates to outcomes that cardiologists measure.

This article is education and reporting on published research. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Talk to your own clinician about your own situation.

Sources

1. Therapeutic applications of natural products in the management of venous diseases: a comprehensive review, Inflammopharmacology (2025).
2. <i>Vitis vinifera</i> L. Leaves as a Source of Phenolic Compounds with Anti-Inflammatory and Antioxidant Potential, Antioxidants (Basel, Switzerland) (2025).
3. Grapevine Wastes: A Rich Source of Antioxidants and Other Biologically Active Compounds, Antioxidants (Basel, Switzerland) (2022).
4. The red-vine-leaf extract AS195 increases nitric oxide synthase-dependent nitric oxide generation and decreases oxidative stress in endothelial and red blood cells, Pharmacology research & perspectives (2016).